Treatment of EAU intermediate risk category non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations. A subgroup analysis of the ‘NIMBUS’ phase III clinical trial.

03 January 2022

Share this on your favourite network: